Day: January 27, 2021

IRVINE, Californie, 27 janv. 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq : CLPT), une société mondiale de plateforme de traitement permettant la navigation et l’acheminement au cerveau, a annoncé aujourd’hui que le Docteur Ernesto Salegio rejoindrait la société le 1er mars 2021 en tant que vice-président, chef de segment de la recherche translationnelle et préclinique au sein de l’équipe chargée de la biologie et de la distribution des médicaments. Le Dr Salegio apporte plus de 19 ans d’expérience dans le domaine des neurosciences translationnelles avec une expertise préclinique directe du système nerveux central (SNC) en matière d’administration des thérapies au cerveau et à la moelle épinière, ainsi que plus de 16 ans d’expérience de thérapie génique avec les vecteurs viraux adéno-associés...

IRVINE, Kalifornien, Jan. 27, 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT), ein weltweit tätiges Unternehmen, das Neuronavigationssysteme für die Durchführung von Eingriffen am Gehirn entwickelt, hat heute bekanntgegeben, dass Ernesto Salegio, PhD, am 1. März 2021 als Vice President, Segment Leader Translational and Pre-Clinical Research Teil des Biologics and Drug Delivery-Teams von ClearPoint wird. Dr. Salegio verfügt über mehr als 19 Jahre Erfahrung in der translationalen Neurowissenschaft mit direkter präklinischer Fachkompetenz im Bereich des zentralen Nervensystems (ZNS) und der Verabreichung von Therapeutika in Gehirn und Rückenmark, einschließlich über 16 Jahren Erfahrung in der Gentherapie mit Adeno-assoziierten viralen Vektoren (AAV).ClearPoint Neuro hat sein Team für Biologics und Drug Delivery 2020 gegründet,...

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time.The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/.Date: February 10, 2021Time: 4:30pm ETListen via Internet: https://investor.pacificbiosciences.com/Toll-free: 888.366.7247International: 707.287.9330Conference ID: 8096067Replay: https://investor.pacificbiosciences.comAbout Pacific BiosciencesPacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing...

GRAND HAVEN, Mich., Jan. 27, 2021 (GLOBE NEWSWIRE) — Access-Power & Co., Inc., (“ACCR or the Company”), a Grand Haven based diversified holding Company is pleased to announce the Company has retained Steve Mills as our Securities Counsel. “We are very excited about his joining our team,” commented Patrick J. Jensen, Director of ACCR.“He will help us and file the Attorney Letter with OTC Markets,” stated Patrick, Director of ACCR. His profile with OTC Markets can be viewed here.https://www.otcmarkets.com/learn/service-providers/8856“Steve comes highly recommended. We have enjoyed getting to know each other,” stated Patrick, “He will represent us in our re-application to up list to OTC Current Information next week with OTC Markets.His complete profile may be viewed here.https://www.linkedin.com/in/steve-millshttps://www.stevemillslaw.comIn...

NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the listing of Intercept’s product on the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) website reached a conclusion regarding the status of a newly identified safety signal (NISS) for Ocaliva® (obeticholic acid) that the Company believes is incorrect.The FDA provides quarterly information on newly identified safety signals. The Company does not believe that the absence of a listed medicine that was in one quarterly update in a subsequent quarter necessarily indicates that the FDA has completed its evaluation of the...

TORONTO, Jan. 27, 2021 (GLOBE NEWSWIRE) — (TSX: DGS, DGS.PR.A) Investors and investment advisors are invited to listen to an update presentation on Dividend Growth Split Corp. (“DGS”) hosted by Chief Investment Officer, Laura Lau of Brompton Funds. Laura provides an update on the fund’s dividend growth portfolio and the market outlook. Brompton believes that Canadian stocks are undervalued and historically dividend growers have outperformed the broader market with lower volatility. The presentation recorded on January 25, 2021 has been posted to the Brompton Funds website at the following link:Dividend Growth Split Corp. UpdateDGS invests in a portfolio consisting primarily of equity securities of large capitalization Canadian dividend growth companies. In addition, DGS may hold up to 20% of the total assets of the portfolio in...

DEERFIELD, Ill., Jan. 27, 2021 (GLOBE NEWSWIRE) — BAB, Inc. (OTCQB: BABB), today announced that its Board of Directors has declared a quarterly distribution of one cent ($0.01) per share, payable on February 24, 2021 to shareholders of record as of February 10, 2021.

BURLINGTON, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2020 financial results on Thursday, February 25, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 8429679. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.About LeMaitre VascularLeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable...

 DBRS raises the ratings on Stellantis N.V.Amsterdam, January 27, 2021 – Stellantis N.V. (NYSE / MTA / Euronext Paris: STLA) (“Stellantis”) announced today that, DBRS Limited (DBRS Morningstar) has upgraded from “BBB (low)” to “BBB” the Issuer Rating and Senior Unsecured Debt rating of Stellantis N.V.The trend on all ratings is stable.About StellantisStellantis is one of the world’s leading automakers and a mobility provider, guided by a clear vision: to offer freedom of movement with distinctive, affordable and reliable mobility solutions.  In addition to the Group’s rich heritage and broad geographic presence, its greatest strengths lie in its sustainable performance, depth of experience and the wide-ranging talents of employees working around the globe. Stellantis will leverage its broad and iconic brand portfolio, which was...

Orange Belgium will publish its results for the fourth quarter and full year of 2020 on Friday, February 5, 2021 at 07:00 CET.Orange Belgium Investor Relations is pleased to invite investors and analysts to participate in an online web conference and/or audio conference call hosted by:Xavier Pichon, CEOArnaud Castille, CFOKoen Van Mol, Investor RelationsThe conference will start at 2:00 pm CET (1:00 pm UK / 8:00 am EST). To access the online web conference, please register using the following link: Orange Belgium FY 2020 results.Should you wish to only join the audio conference call, please register using the same link, where you will find all conference call details.The recorded session will be available after the conference call and can be downloaded from our website. You will find the link to access the recorded session on the website...